• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Gyre Therapeutics, Inc. - Common Stock (NQ:GYRE)

    7.160 -0.170 (-2.32%)
    Delayed Quote Updated: 11:22 AM EDT, Oct 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 23,062
    Open 7.350
    Bid (Size) 7.110 (100)
    Ask (Size) 7.190 (200)
    Prev. Close 7.330
    Today's Range 7.100 - 7.380
    52wk Range 5.440 - 9.420
    Shares Outstanding 37,759,825
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Gyre Therapeutics to Participate in Upcoming September Investor Conferences
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
    From Gyre Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +5.1%
    +5.1%
    1 Month
    +9.0%
    +9.0%
    3 Month
    +9.8%
    +9.8%
    6 Month
    -1.0%
    -1.0%
    1 Year
    -4.0%
    -4.0%

    More News

    Read More
    News headline image
    Gyre Therapeutics Appoints Three New Members to its Board of Directors
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead ↗
    Via Stocktwits
    News headline image
    Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Inc (NASDAQ:GYRE) Reports Q3 2025 Earnings Beat Amid Revenue Miss and Lowered Guidance ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Earnings Scheduled For November 7, 2025 ↗
    Via Benzinga
    News headline image
    Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    Elastic, Applied Digital, Eightco Holdings And Other Big Stocks Moving Higher On Friday ↗
    Via Benzinga
    News headline image
    This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
    Via Benzinga
    BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone
    Via Investor Brand Network
    News headline image
    Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker ↗
    Via Benzinga
    News headline image
    This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗
    Via Benzinga
    News headline image
    Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
    From Gyre Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
    From Gyre Therapeutics Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Gyre Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Gyre Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Gyre Therapeutics, Inc. - Common Stock trade on?
    Gyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Gyre Therapeutics, Inc. - Common Stock?
    The ticker symbol for Gyre Therapeutics, Inc. - Common Stock is GYRE on the Nasdaq Stock Market
    What is the current price of Gyre Therapeutics, Inc. - Common Stock?
    The current price of Gyre Therapeutics, Inc. - Common Stock is 7.160
    When was Gyre Therapeutics, Inc. - Common Stock last traded?
    The last trade of Gyre Therapeutics, Inc. - Common Stock was at 10/01/26 11:22 AM ET
    What is the market capitalization of Gyre Therapeutics, Inc. - Common Stock?
    The market capitalization of Gyre Therapeutics, Inc. - Common Stock is 270.36M
    How many shares of Gyre Therapeutics, Inc. - Common Stock are outstanding?
    Gyre Therapeutics, Inc. - Common Stock has 270M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.